Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Elizabeth H Phillips, Amy A Kirkwood, Christina Hague, Jorgen Vestbo, Massimo Federico, Francesco D'Amore, Alexander Fossa, Judith Trotman, Leanne Berkahn, Daniel L. Molin, Stefano Luminari, Sally F Barrington, Peter Johnson, John Radford

Blood (2023) 142 (Supplement 1): 612.

https://doi.org/10.1182/blood-2023-185818

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Judith Trotman, Pier Luigi Zinzani, Yuqin Song, Richard Delarue, Gisoo Barnes, Pil Kim, Elena Ivanova, Boxiong Tang, Jiří Mayer, Ana C. De Oliveira, Sarit Assouline, Christopher R. Flowers

Blood (2023) 142 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2023-181195

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival

Blood (2023) 142 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2023-185879

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

Journal Articles

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Yoon Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael L. Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason Paik, Amit Agarwal, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2023-180109

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Anne Ségolène Cottereau, Louis Rebaud, Judith Trotman, Pierre Feugier, Loretta J. Nastoupil, Emmanuel Bachy, Ian W. Flinn, Corinne Haioun, Loic Ysebaert, Nancy L. Bartlett, Hervé Tilly, René-Olivier Casasnovas, Romain Ricci, Cedric Portugues, Irène Buvat, Michel Meignan, Franck Morschhauser

Blood (2022) 140 (Supplement 1): 6474–6476.

https://doi.org/10.1182/blood-2022-159207

Published: 2022

Journal Articles

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Blood (2022) 140 (Supplement 1): 1476–1478.

https://doi.org/10.1182/blood-2022-158883

Published: 2022

Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Blood (2022) 140 (Supplement 1): 573–576.

https://doi.org/10.1182/blood-2022-163371

Published: 2022

Journal Articles

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Stefano Luminari, Alexander Fosså, Judith Trotman, Daniel Molin, Francesco Annibale d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A. Kirkwood, Peter Johnson

Blood (2022) 140 (Supplement 1): 766–767.

https://doi.org/10.1182/blood-2022-162780

Published: 2022

Journal Articles

CAR-T for follicular lymphoma: are we good to go?

Robin Gasiorowski, Judith Trotman

Blood (2022) 140 (8): 799–800.

https://doi.org/10.1182/blood.2022017279

Published: 2022

Journal Articles

Is it time for PET-guided therapy in follicular lymphoma?

Judith Trotman, Andrew R. Pettitt

Blood (2022) 139 (11): 1631–1641.

https://doi.org/10.1182/blood.2020008243

Published: 2022

Journal Articles

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Emma Verner, Amanda Johnston, Nalini Pati, Eliza Hawkes, Hui-Peng Lee, Tara Cochrane, Chan-Yoon Cheah, Robin J Filshie, Duncan Purtill, Hanlon Sia, Anoop Kumar Enjeti, Christina Brown, Nicholas E. Murphy, Jennifer Curnow, Kenneth Lee, Mannu Walia, Belinda Butcher, Judith Trotman

Blood (2021) 138 (Supplement 1): 304.

https://doi.org/10.1182/blood-2021-149019

Published: 2021

Journal Articles

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Judith Trotman, Peter Presgrave, Duncan P. Carradice, Douglas Stuart Lenton, Maher Gandhi, Tara Cochrane, Xavier Badoux, Gloria Nkhoma, Belinda Butcher, Michael Fulham, Anna Johnston

Blood (2021) 138 (Supplement 1): 2428.

https://doi.org/10.1182/blood-2021-146343

Published: 2021

Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 183.

https://doi.org/10.1182/blood-2021-148302

Published: 2021

Journal Articles

Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data

Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, Peter Liburdi deNardis, Michelle Postek, Shirley D'Sa, Marie José Kersten, Sheeba K Thomas, M. Lia Palomba, Adam J. Olszewski, Newton Guerin, Clare Scott, Judith Trotman

Blood (2021) 138 (Supplement 1): 1343.

https://doi.org/10.1182/blood-2021-147720

Published: 2021

Journal Articles

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia

Brendan Beaton, Sarah C Sasson, Katherine Rankin, Juliette Raedemaeker, Alexander Wong, Priyanka Hastak, Andrew Warden, Alberto Ospina Stella, Anupriya Aggarwal, Ian D Caterson, Chansavath Phetsouphanh, Stuart Turville, Anthony D Kelleher, Fabienne Brilot, Judith Trotman

Blood (2021) 138 (Supplement 1): 816.

https://doi.org/10.1182/blood-2021-149348

Published: 2021

Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134440

Published: 2020

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

NARROW

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

Genomic profiling for clinical decision making in lymphoid neoplasms

Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

CAR-T for follicular lymphoma: are we good to go?

Is it time for PET-guided therapy in follicular lymphoma?

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only